Explore the groundbreaking advancements in inhaled drug delivery, a transformative approach that promises enhanced efficacy and patient convenience

Inhalation products provide a patient-centric approach to delivering therapeutics directly to the lungs: with an estimated 800 million people suffering from chronic respiratory diseases worldwide, major potential for greater utility exists.

One of the pioneers of inhaled therapies, David Jack discovered countless drugs to treat asthma and similar conditions.

Inhaled biologics are being evaluated as an alternative to injections for treating rare and serious diseases. Experts touch on several challenges including making stable and safe formulations of inhaled biologics.

Our Inhaled Therapeutics discussion group brought together key experts in the field of dry powder formulation to discuss their research into both formulation and process.

Our expert panel discuss the process of ensuring that inhalation devices are not burdensome to use.

When designing drug-delivery devices, the patient must be at the centre of the development process. Nélio Drumond of Takeda Pharmaceuticals discusses how this patient-centric approach allows the design to maximise efficiency and efficacy.

Recipharm offers inhalation and nasal product development services in compliance with regulatory guidelines from the ICH, EMA and FDA.

Inhaled drugs are a viable means of targeting tobacco smoke-related diseases in the lungs: permeability is key to their successful delivery. This Commentary article explores the mechanisms by which drugs are delivered across cell membranes, as well as pertinent areas for present and future research.

This month, the discussion group debated the advantages and disadvantages of different types of inhalers. One key area of interest was current-day challenges with aerosol delivery, which could be addressed through smart inhalers and other innovative new devices.